Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clofarabine
- Development stage
- Approved
- Lead developer
- Sanofi
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Clofarabine is a second-generation purine nucleoside antimetabolite used primarily as an antineoplastic agent. It is approved for the treatment of pediatric patients (ages 1 to 21) with relapsed or refractory acute lymphoblastic leukemia (ALL) after at least two prior regimens[3][5]. The drug acts by inhibiting ribonucleotide reductase and DNA polymerase, leading to inhibition of DNA synthesis and repair, which induces apoptosis in rapidly dividing malignant cells[7]. It has also been studied in other hematologic malignancies such as acute myeloid leukemia (AML), juvenile myelomonocytic leukemia (JMML), and various lymphomas[1][10]. Clofarabine is administered intravenously.
- Brand names
- ClolarEvoltra
- Other names
- ClofarabinClofarabinaClofarabinum2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine
02
Targets
RNR (Ribonucleotide reductase)POLA1 (DNA polymerase alpha)
Beyond the preview
Go deeper on clofarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clofarabine.